Document is current

Any future updates will be listed below

Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis

Crossref DOI link: https://doi.org/10.1007/s12325-022-02101-9

Published Online: 2022-04-08

Published Print: 2022-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark